Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
28.40
-1.28 (-4.31%)
Streaming Delayed Price
Updated: 12:41 PM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
Today 8:00 EDT
From
UroGen Pharma Ltd.
Via
GlobeNewswire
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 13, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at Upcoming Investor Conferences
May 07, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
May 06, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
April 29, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
March 13, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
March 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
March 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
February 27, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
February 23, 2026
Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
February 04, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
January 05, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
November 06, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
November 06, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
November 04, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
October 30, 2025
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
October 27, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
October 02, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at Upcoming Investor Conferences
August 21, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
August 07, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 05, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
July 29, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit
July 28, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
July 28, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
